<DOC>
	<DOC>NCT02329223</DOC>
	<brief_summary>This was a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of omalizumab administered subcutaneously as an add-on therapy for the treatment of adolescent and adult participants 12 - 75 years who received the diagnosis of refractory chronic spontaneous uriticaria and who remained symptomatic despite standard-dosed non-sedating H1 antihistamine treatment.</brief_summary>
	<brief_title>Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Key Diagnosis of chronic spontaneous urticaria refractory to H1 antihistamine at the time of randomization Chronic spontaneous urticaria diagnosis for 6 months Key Weight less than 20 kg Clearly defined underlying etiology for chronic urticaria other than chronic spontaneous urticaria Evidence of parasitic infection Any other skin diseases than chronic spontaneous urticaria with chronic itching Previous treatment with omalizumab Contraindications to diphenhydramine History of anaphylactic shock History or current diagnosis of ECG abnormalities indicating significant risk of safety for patients participating in the study History of hypersensitivity to omalizumab or to drugs of similar chemical classes Pregnant or nursing (lactating) women</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Chronic spontaneous uriticaria</keyword>
	<keyword>Omalizumab</keyword>
</DOC>